ES2487637T3 - Moduladores de PDZ Disheveled - Google Patents

Moduladores de PDZ Disheveled Download PDF

Info

Publication number
ES2487637T3
ES2487637T3 ES11154863.2T ES11154863T ES2487637T3 ES 2487637 T3 ES2487637 T3 ES 2487637T3 ES 11154863 T ES11154863 T ES 11154863T ES 2487637 T3 ES2487637 T3 ES 2487637T3
Authority
ES
Spain
Prior art keywords
disheveled
pdz
terminus
internal region
pdz modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11154863.2T
Other languages
English (en)
Inventor
Mike Costa
Sachdev S. Sidhu
Yingnan Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2487637T3 publication Critical patent/ES2487637T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Image Processing (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)

Abstract

Polipéptido aislado que comprende una región con extremo N o interna que se une a PDZ de Dvl, en el que dicha región con extremo N o interna comprende la secuencia de aminoácidos X1-X2-W-X3-D-X4-P, y en el que X1 es L o V, X2 es L, X3 es S o T, y X4 es I, F o L, y en el que el polipéptido inhibe la señalización de Wnt mediada por Dvl endógena.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31

Claims (1)

  1. imagen1
ES11154863.2T 2006-04-10 2007-04-09 Moduladores de PDZ Disheveled Active ES2487637T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79067306P 2006-04-10 2006-04-10
US790673P 2006-04-10

Publications (1)

Publication Number Publication Date
ES2487637T3 true ES2487637T3 (es) 2014-08-22

Family

ID=38537937

Family Applications (2)

Application Number Title Priority Date Filing Date
ES07760350T Active ES2385261T3 (es) 2006-04-10 2007-04-09 Moduladores de PDZ Disheveled
ES11154863.2T Active ES2487637T3 (es) 2006-04-10 2007-04-09 Moduladores de PDZ Disheveled

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES07760350T Active ES2385261T3 (es) 2006-04-10 2007-04-09 Moduladores de PDZ Disheveled

Country Status (9)

Country Link
US (2) US7695928B2 (es)
EP (2) EP2002259B1 (es)
JP (1) JP5290148B2 (es)
CN (2) CN101467039B (es)
AU (1) AU2007238186B2 (es)
CA (1) CA2648322C (es)
ES (2) ES2385261T3 (es)
HK (1) HK1131438A1 (es)
WO (1) WO2007121147A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI615403B (zh) * 2007-02-21 2018-02-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
KR101278073B1 (ko) * 2008-08-04 2013-06-24 연세대학교 산학협력단 Ｉｄｂｆ의 신규 용도
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
CN113398268A (zh) 2012-02-11 2021-09-17 霍夫曼-拉罗奇有限公司 R-spondin易位及其使用方法
GB201220891D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating breast cancers
GB201220901D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating pancreatic cancer
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
US9520180B1 (en) 2014-03-11 2016-12-13 Hypres, Inc. System and method for cryogenic hybrid technology computing and memory
GB201421647D0 (en) 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8319174D0 (en) * 1983-07-15 1983-08-17 Erba Farmitalia Biologically active heptapeptides
GB8430255D0 (en) 1984-11-30 1985-01-09 Erba Farmitalia Biologically active oligopeptides
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
CA2345497A1 (en) 1988-10-28 1990-04-28 Genentech, Inc. Growth hormone variants and method for forming growth hormone variants
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5688936A (en) * 1992-06-11 1997-11-18 The Regents Of The University Of California Vesicle membrane transport proteins
WO1994012158A1 (en) 1992-12-02 1994-06-09 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
PT779806E (pt) 1994-09-09 2001-02-28 Takeda Chemical Industries Ltd Preparacao de libertacao sustentada contendo um sal metalico de um peptido
IL122385A (en) 1995-06-07 2001-01-11 Alkermes Inc Composition for sustained release of human growth hormone
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6294330B1 (en) 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
WO2000006717A2 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
US6610836B1 (en) * 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
WO2002090544A2 (en) * 2001-05-04 2002-11-14 Hybrigenics Protein-protein interactions in adipocyte cells (3)
EP1493028A4 (en) * 2001-07-06 2006-06-14 Genentech Inc PHAGEN DISPLAY PRESENTED LIGANDS OF THE PDZ DOMAIN
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
WO2004032838A2 (en) 2002-10-04 2004-04-22 The Regents Of The University Of California Methods for treating cancer by inhibiting wnt signaling
CA2572469A1 (en) * 2004-07-01 2006-01-19 The Regents Of The University Of California Small molecule inhibition of a pdz-domain interaction

Also Published As

Publication number Publication date
US7695928B2 (en) 2010-04-13
AU2007238186A1 (en) 2007-10-25
CA2648322A1 (en) 2007-10-25
CN101467039B (zh) 2013-11-06
CA2648322C (en) 2017-11-28
ES2385261T3 (es) 2012-07-20
EP2343551A1 (en) 2011-07-13
EP2343551B1 (en) 2014-05-28
CN101467039A (zh) 2009-06-24
CN103351425A (zh) 2013-10-16
US20100136580A1 (en) 2010-06-03
EP2002259B1 (en) 2012-05-16
EP2002259A2 (en) 2008-12-17
US7977064B2 (en) 2011-07-12
US20080167386A1 (en) 2008-07-10
WO2007121147A2 (en) 2007-10-25
JP5290148B2 (ja) 2013-09-18
CN103351425B (zh) 2016-01-20
HK1131438A1 (en) 2010-01-22
AU2007238186B2 (en) 2014-01-09
JP2009533465A (ja) 2009-09-17
WO2007121147A3 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
ES2487637T3 (es) Moduladores de PDZ Disheveled
ES2486675T3 (es) Análogo de péptido de oxintomodulina
ES2523837T3 (es) Agentes de unión específica al factor de crecimiento de hepatocitos
ES2512141T3 (es) Análogo peptídico de oxintomodulina
ES2525477T3 (es) Anticuerpos anti-factor D humanizados
ES2629749T3 (es) Inmunidad tumoral
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
CO5720212A1 (es) Composicion de anticuerpo her2
ES2665917T3 (es) Endoxifeno para su uso en el tratamiento del cáncer
ES2548238T3 (es) Formulaciones antagonistas de VEGF
ES2507094T3 (es) Proteína específica del timo
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2577203T3 (es) Página de información
EA200700973A1 (ru) Слитый белок, содержащий домен bh3 белка «вh3-только»
DE602006018856D1 (de) Neue nutrazeutika-zusammensetzungen
ES2513392T3 (es) Materiales biológicos y usos de los mismos
ES2585185T3 (es) Polipéptidos quiméricos y sus aplicaciones terapéuticas contra una infección por Flaviviridae
CL2012002522A1 (es) Composición farmacéutica que comprende un compuesto inhibidor de dpp iv con un grupo amino o una sal del mismo , un primer diluyente , un segundo diluyente ,un aglutinante , un disgregante y un lubricante, útil en el tratamiento de diabetes mellitus.
CR9975A (es) Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de calcitonina
CR9452A (es) Agentes terapeuticos a base de peptidos de toxinas
PE20120532A1 (es) ANTICUERPOS ANTI-ActRIIB
EA200901365A1 (ru) Стабилизированная фармацевтическая композиция, содержащая прегабалин
UY28641A1 (es) Anticuerpos
ES2481641T3 (es) Uso de receptor inmunosupresor
AR065370A1 (es) Moduladores de htra1 - pdz y htra3 pdz